AC
NLSPW

Ayrton Capital’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Ayrton Capital’s Portfolio NLSPW Stock Details NLSPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$17.9K Hold
170,100
– – 0.12% 29
2023
Q2 		$18.2K Hold
170,100
– – 0.11% 28
2023
Q1 		$25.5K Hold
170,100
– – 0.09% 32
2022
Q4 		$49.3K Hold
170,100
– – 0.13% 35
2022
Q3 		$43K Hold
170,100
– – 0.08% 51
2022
Q2 		$20K Hold
170,100
– – 0.03% 64
2022
Q1 		$65K Hold
170,100
– – 0.08% 65
2021
Q4 		$85K Buy
+170,100
New +$110K 0.08% 75

Other funds holding NLSPW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Ayrton Capital's NLSPW Position: Q3 2023 in Review

Ayrton Capital held its NLS Pharmaceutics Warrant (NLSPW) position steady in Q3 2023 at 170,100 shares worth $17.9K. The position accounts for 0.12% of the portfolio, ranked #29.

Ayrton Capital first reported a position in NLSPW in Q4 2021 and has held it in 8 quarters since. The position peaked at $85K in Q4 2021. 5 funds tracked by Wall St. Rank hold NLSPW as of Q3 2023.

  • Ayrton Capital held 170,100 shares of NLS Pharmaceutics Warrant worth $17.9K as of Q3 2023.
  • Ayrton Capital left its NLS Pharmaceutics Warrant share count unchanged in Q3 2023.
  • NLS Pharmaceutics Warrant made up 0.12% of Ayrton Capital's portfolio in Q3 2023, its #29 holding.
  • Ayrton Capital first reported a position in NLS Pharmaceutics Warrant in Q4 2021 and has held it in 8 quarters since.
  • Ayrton Capital's NLS Pharmaceutics Warrant position peaked at $85K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q3 2023.

Based on Ayrton Capital's 13F filing for Q3 2023, filed 13 Nov 2023.